業績 | 東北大学大学院医学系研究科・加藤研究室

原著（-2016年度）

-2016年

＊PubMed：加藤の2003年以降の業績　
＊Google scholar：加藤の業績の引用

101．Ohka F,Yamamichi A, Kurimoto M, Motomura K, Tanahashi K, Suzuki H, Aoki K, Deguchi S, Chalise L, Hirano M, Kato A, Nishimura Y, Hara M, Kato Y, Wakabayashi T, Natsume A.

A Novel All-in-one Intraoperative Genotyping System for IDH1-mutant Glioma

Brain Tumor Pathol., in press
100. Fujii Y, Kaneko MK, Ogasawara S, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Honma R, Kato Y.
(*corresponding author)

Development of RAP Tag, a Novel Tagging System for Protein Detection and Purification

Monoclon. Antib. Immunodiagn. Immunother., doi:10.1089/mab.2016.0052. (PDF)
PDIS
98. Kato Y*, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK*
(*corresponding author)

Anti-Glycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity

Monoclon. Antib. Immunodiagn. Immunother., 36(1): 20-24, 2017 (PDF)
PDIS

97．Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y*.
(*corresponding author)

Chimeric Anti-human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain

Monoclon. Antib. Immunodiagn. Immunother., 36(1): 25-29, 2017 (PDF)
PDIS
96．Takara K, Maruo N, Oka K, Kaji C, Hatakeyama Y, Sawa N, Kato Y, Yamashita J, Kojima H, Sawa Y.

Morphological study of tooth development in podoplanin-deficient mice

PLoS One., PLoS One. 2017 Feb 21;12(2):e0171912.
95．Kaneko MK, Nakamura T, Honma R, Ogasawara S, Fujii Y, Abe S, Takagi M, Harada H, Suzuki H, Nishioka Y, Kato Y*.
(*corresponding author)

Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN
Open Access

Cancer Med., 6(2); 382–396, 2017
PDIS
94．Ogasawara S, Honma R, Kaneko MK, Fujii Y, Kagawa Y, Konnai S, Kato Y*
(*corresponding author)

Podoplanin Expression in Canine Melanoma
Open Access

Monoclon. Antib. Immunodiagn. Immunother., 35(6): 304-306, 2016 (PDF)
PDIS
93. Fujii Y, Kaneko MK, Kato Y*.
(*corresponding author)

MAP tag: A novel tagging system for protein purification and detection.
Open Access

Monoclon. Antib. Immunodiagn. Immunother., 35(6): 293-299, 2016 (PDF)
PDIS
92．Ogasawara S, Fujii Y, Kaneko MK, Oki H, Sabit H, Nakada M, Suzuki H, Ichimura K, Komori T, Kato Y*.
(*corresponding author)

Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6.
Open Access

Monoclon. Antib. Immunodiagn. Immunother., 35(5): 254-258, 2016 (PDF)
PDIS
91．Kaneko MK, Honma R, Ogasawara S, Fujii Y, Nakamura T, Saidoh N, Takagi M, Kagawa Y, Konnai S, Kato Y*.
(*corresponding author)

PMab-38 recognizes canine podoplanin of squamous cell carcinomas.

Monoclon. Antib. Immunodiagn. Immunother., 35(5): 263-266, 2016 (PDF)
PDIS
90. Ogasawara S, Kaneko MK, Kato Y*
(*corresponding author)

LpMab-19 Recognizes Sialylated O-glycan on Thr76 of Human Podoplanin

Monoclon. Antib. Immunodiagn. Immunother.,35(5): 245-253, 2016 (PDF)
PDIS
89．Hayashi A, Misumi K, Shibahara J, Kokudo N, Kato Y and Fukayama M.

Immunohistochemistry Using Monoclonal Antibody MsMab-2 Is Useful to Detect IDH1 R132L in Intrahepatic Cholangiocarcinoma.

Pathology international, 66(10); 578–582, 2016 (PDF)
PDIS
88．Yamamichi A, Kasama T, Ohka F, Suzuki H, Kato A, Motomura K, Hirano M, Ranjit M, Chalise L, Kurimoto K, Kondo G, Aoki K, Kaji N, Tokeshi M, Matsubara T, Senga T, Kaneko MK, Suzuki H, Wakabayashi T, Baba Y, Kato Y, Natsume A.

An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas

Sci Technol Adv Mater.,17; 618-625, 2016 (PDF)
PDIS
87．Kitago Y, Kaneko MK, Ogasawara S, Kato Y*, Takagia J*.
(*corresponding author)

Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1

Biochemical and Biophysical Research Communications, 478(3):1274-9., 2016 (PDF)
PDIS
86. Umitsu M, Sakai K, Ogasawara S, Kaneko MK, Asaki R, Tamura-Kawakami K, Kato Y, Matsumoto K, Takagi J.

Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies
Open Access

Scientific Reports,6, Article number: 33149 (PDF)
PDIS
85．Honma R, Kaneko MK, Ogasawara S, Fujii Y, Konnai S, Takagi M, Kato Y*
(*corresponding author)

Specific Detection of Dog Podoplanin Expressed in Renal Glomerulus by A Novel Monoclonal Antibody PMab-38 in Immunohistochemistry.

Monoclon. Antib. Immunodiagn. Immunother.,35(4): 212-216, 2016 (PDF)
PDIS
84．Honma R, Ogasawara S, Kaneko MK, Fujii Y, Oki H, Nakamura T, Takagi M, Konnai S, Kato Y * (*corresponding author)

PMab-44 Detects Bovine Podoplanin in Immunohistochemistry

Monoclon. Antib. Immunodiagn. Immunother.,35(4): 186-190, 2016(PDF)
PDIS
83．Kato Y*, Ogasawara S, Oki H, Goichberg P, Honma R, Fujii Y, Kaneko MK.
(*corresponding author)

LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-glycan on Thr52 of Platelet Aggregation-stimulating Domain of Human Podoplanin
Open Access

PLoS ONE,11(3): e0152912., 2016 (PDF)
PDIS
82． Kato Y*, Ogasawara S, Oki H, Honma R, Takagi M, Fujii Y, Nakamura T, Saidoh N, Kanno H, Umetsu M, Kamata S, Kubo H, Yamada M, Sawa Y, Morita K, Harada H, Suzuki H, Kaneko MK.
(*corresponding author)

Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin

Monoclon. Antib. Immunodiagn. Immunother., 35(2): 109-116, 2016 (PDF)
PDIS
81. Ogasawara S, Kaneko MK, Honma R, Oki H, Fujii Y, Takagi M, Suzuki H, Kato Y*
(*corresponding author)

Establishment of Mouse Monoclonal Antibody LpMab-13 against Human Podoplanin

Monoclon. Antib. Immunodiagn. Immunother.,35(3):155-162, 2016(PDF)
PDIS
80．Fujii Y, Matsunaga Y, Arimori T, Kitago Y, Ogasawara S, Kaneko MK, Kato Y, Takagi J.

Tailored placement of a turn-forming PA tag into the structured domain of a protein to probe its conformational state

J Cell Sci,,29(7):1512-22, 2016(PDF)
PDIS
79．Honma R, Fujii Y, Ogasawara S, Oki H, Konnai S, Kagawa Y, Takagi M, Kaneko MK, Kato Y * (*corresponding author)

Critical Epitope of Anti-Rabbit Podoplanin Monoclonal Antibodies for Immunohistochemical Analysis

Monoclon. Antib. Immunodiagn. Immunother., 35(2): 65-72, 2016(PDF)
PDIS
78．Honma R, Fujii Y, Ogasawara S, Oki H, Liu X, Nakamura T, Kaneko MK, Takagi M, Kato Y* (*corresponding author)

Establishment of a novel monoclonal antibody PMab-32 against rabbit podoplanin

Monoclon. Antib. Immunodiagn. Immunother., 35(1): 41-47, 2016 (PDF)
PDIS
77．Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Okada N, Miyamoto R, Sato C, Tobiume M, Otsuka K, Tsuchiya K, Kawazoe K, Ogasawara S, Kato Y, and Nishioka Y.

Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in orthotopic xenograft model
Open Access

Cancer Sci.,107, 1198–1205, 2016(PDF)
PDIS
76．Takano S, Ishikawa E, Sakamoto N, Matsuda M, Akutsu H, Noguchi M, Kato Y, Yamamoto T, Matsumura A.

Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas

Brain Tumor Pathol.,33(2):107-116, 2016 (PDF)
75．Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A.

CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains

Cancer Immunol Res.;4(3):259-68.,2016 (PDF)
PDIS
74．Maekawa N, Konnai S, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Takagi S, Kagawa Y, Nakajima C, Suzuki Y, Kato Y, Murata S, Ohashi K.

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers
Open Access

PLoS ONE; 11(6):e0157176, 2016 (PDF)
PDIS
73．Kato Y*, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, and Kaneko MK.
(*corresponding author)

The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.

Oncotarget, 6(34): 36003-36018, 2015 (PDF)
PDIS
72．Kato Y.*
(*corresponding author)

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.

Brain Tumor Pathol.,32(1): 3-11, 2015
PDIS
71． Kaneko MK, Oki H, Hozumi Y, Liu X, Ogasawara S, Takagi M, Goto K, Kato Y*
(*corresponding author)

A monoclonal antibody LpMab-9 recognizes O-glycosylated N-terminus of human podoplanin.

Monoclon. Antib. Immunodiagn. Immunother.,34(5): 310-317, 2015 (PDF)
PDIS
70．Kaneko MK, Oki H, Ogasawara S, Takagi M, Kato Y*
(*corresponding author)

An anti-podoplanin monoclonal antibody LpMab-7 detects metastatic lesions of osteosarcoma

Monoclon. Antib. Immunodiagn. Immunother., 34(3): 154-161, 2015 (PDF)
PDIS
69．Ogasawara S, Oki H, Kaneko MK, Hozumi Y, Liu X, Honma R, Fujii Y, Nakamura T, Goto K, Takagi M, Kato Y*
(*corresponding author)

Development of a monoclonal antibody LpMab-10 recognizing non-glycosylated PLAG1/2 domain including Thr34 of human podoplanin.

Monoclon. Antib. Immunodiagn. Immunother., 34(5): 318-326, 2015 (PDF)
PDIS
68．Fujii Y, Ogasawara S, Oki H, Liu X, Kaneko MK, Takano S, Kato Y*
(*corresponding author)

A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas

Biochem Biophys Res Commun., 466(4),733–739, 2015
PDIS
67．Oki H, Honma R, Ogasawara S, Fujii Y, Liu X, Kaneko MK, Takagi M, Kato Y*
(*corresponding author)

Development of a sensitive monoclonal antibody PMab-2 against rat podoplanin

Monoclon. Antib. Immunodiagn. Immunother., 34(6): 396-403, 2015 (PDF)
PDIS
66．Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, Kato Y*
(*corresponding author)

Characterization of a monoclonal antibody LpMab-7 recognizing non-PLAG domain of podoplanin

Monoclon. Antib. Immunodiagn. Immunother., 34(3): 174-180, 2015 (PDF)
PDIS
65．Oki H, Ogasawara S, Kaneko MK, Takagi M, Yamauchi Y, Kato Y.*
(*corresponding author)

Characterization of a monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.

Monoclon. Antib. Immunodiagn. Immunother.,34(1): 44-50, 2015
PDIS
64．Liu X, Ogasawara S, Kaneko MK, Oki H, Hozumi Y, Goto K, Takagi M, Kato Y.*
(*corresponding author)

A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma

Biochem Biophys Res Commun., 459(4),636–642, 2015
PDIS
63．Ochoa-Alvarez JA, Krishnan H, Pastorino JG, Nevel E, Kephart D, Shen Y, Fatahzadeh M, Baredes S, Kalyoussef E, Honma M, Adelson ME, Kaneko MK, Kato Y, Yin K, Shienbaum AJ, Jensen LD, and Goldberg GS.

Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.

Oncotarget,6(11),9045-9060,2015
PDIS
62．Ikota H, Nobusawa S, Arai H, Kato Y, Ishizawa K, Hirose T, Yokoo H.

Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies

Brain Tumor Pathol., 32(4):237-44, 2015
PDIS
61．Takano S, Kato Y, Yamamoto T, Liu X, Ishikawa E, Kaneko MK, Ogasawara S, Matsuda M, Noguchi M, Matsumura A.

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.

Brain Tumor Pathol., July 2015, Volume 32, Issue 3, pp 169-175
PDIS
60．Kato Y* and Kaneko MK.
(*corresponding author)

A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin.

Sci Rep 4, 5924, 2014（@東北大学）（注目の論文）
PDIS
59．Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.*
(*corresponding author)

IDH2 mutation is frequently observed in giant cell tumor of bone.

Cancer Sci.,105(6),744-8,2014 （医化学、山形大学整形外科との共同研究@東北大学）PDIS
58．Fujii Y, Kaneko M, Neyazaki M, Nogi T, Kato Y*, Takagi J*
(*corresponding author)

PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin.

Protein Expr Purif. Volume 95, 240-247, 2014 (pdf)（大阪大学との共同研究@東北大学）PDIS
57．Moriya K, Kaneko MK, Liu X, Hosaka M, Fujishima F, Watanabe M, Ogasawara S, Sakuma J, Sasahara Y, Kure S, Kato Y*
(*corresponding author)

IDH2 and TP53 mutations are correlated with gliomagenesis in a patient with Maffucci syndrome.

Cancer Sci., 105(3),359-362,2014（小児科、整形外科との共同研究@東北大学）PDIS
56．Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y.

A novel platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and non-glycosylated rhodocytin.

Structure, Volume 22, Issue 12, p1711–1721, 2 December 2014 （理研との共同研究@東北大学）
PDIS
55．Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, Soga T, Natsume A.

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutaion

Tumor Biol., 35(6):5911-20（名古屋大学、慶応大学先端研との共同研究@東北大学）PDIS
54．Maruyama Y, Maruyama K, Kato Y, Kajiya K, Moritoh S, Yamamoto K, Matsumoto Y, Kerjaschki D, Nakazawa T, Kinoshita S.

The Effect of Podoplanin Inhibition on Lymphangiogenesis under Pathological Conditions.

Invest Ophthalmol Vis Sci., 55:4813-4822; 2014（眼科との共同研究@東北大学）PDIS
53．Sabit H, Nakada M, Furuta T, Watanabe T, Hayashi Y, Sato H, Kato Y, Hamada JI.

Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence

Brain Tumor Pathol., Oct;31(4):242-6. (pdf)（金沢大学との共同研究@東北大学）
52．Kato Y* and Kaneko MK.
(*corresponding author)

Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation

Biochem Biophys Res Commun., 433(4), 374?378, 2013 (pdf)（@山形大学）PDIS
51．Kato Y*, Natsume A, Kaneko MK.
(*corresponding author)

A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation

Biochem Biophys Res Commun., 432(4):564-7, 2013 (pdf)（名古屋大学との共同研究@山形大学）PDIS
50．Kaneko MK, Ogasawara S, Kato Y*.
(*corresponding author)

Establishment of a novel multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.

TJEM, 230: 103-109, 2013（@東北大学）PDIS
49．Kaneko MK, Tsujimoto Y, Hozumi Y, Goto K, Kato Y*.
(*corresponding author)

Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations

Monoclon. Antib. Immunodiagn. Immunother., 32(3), 224-228, 2013 (PDF)（山形大学解剖学との共同研究@山形大学）PDIS
48．Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, Kato Y*
(*corresponding author)

Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations

Biochem Biophys Res Commun., 432(1):40-5, 2013（東北大学、名古屋大学との共同研究@山形大学）PDIS
47．Ogasawara S, Kaneko MK, Tsujimoto Y, Liu X, Kato Y*.
(*corresponding author)

A Multi-specific Monoclonal Antibody MsMab-2 Recognizes IDH1-R132L and IDH2-R172M Mutations.

Monoclon. Antib. Immunodiagn. Immunother., 32(6), 377-381, 2013 (pdf)（@東北大学）PDIS
46．Liu X, Kato Y*, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M.
(*corresponding author)

Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.

Cancer Med.,2(6): 803?814, 2013 (PDF)（山形大学整形外科との共同研究@東北大学）PDIS
45．Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y

A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.

J. Immunol., 190(12):6239-49 (pdf)（徳島大学との共同研究@山形大学）PDIS
44．Chandramohan V, Bao X, Kaneko MK, Kato Y, Keir ST, Szafranski S, Kuan CT, Pastan I, Bigner DD.

Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors

Int. J. Cancer;132(10):2339-48, 2013 (pdf)（@Duke大学）
43．Yoshikawa A, Nakada M, Watanabe T, Hayashi Y, Sabit H, Kato Y, Suzuki S, Ooi A, Sato H, Hamada JI.

Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.

Brain Tumor Pathol., 30(3):175-9, 2013 (pdf)（金沢大学との共同研究@山形大学）
42．Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y*.
(*corresponding author)

Chimeric anti-podoplanin antibody suppresses tumor metastasis via neutralization and antibody-dependent cellular cytotoxicity

Cancer Sci., 103 (11), 1913?1919, 2012 (pdf)（東京大学との共同研究@山形大学）
41．Chiaki Kaji, Yuta Tsujimoto, Mika Kato Kaneko, Yukinari Kato*, and Yoshihiko Sawa*.
(*corresponding author)

Immunohistochemical Examination of Novel Rat Monoclonal Antibodies against Mouse and Human Podoplanin.

Acta Histochm. Cytochem., 45 (4): 227-237, 2012 (pdf)（福岡歯科大学との共同研究@山形大学）
40．Takano S, Kato Y*, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, Matsumura A.
(*corresponding author)

Immunohistochemical detection of IDH1 mutation, p53 and internexin as a prognostic factor of glial tumors

J Neurooncol. 2012 Jul;108(3):361-73（筑波大学との共同研究@山形大学）
39．Hatakeyama K, Kaneko MK, Kato Y*, Ishikawa T, Nishihira K, Tsujimoto Y, Shibata Y, Ozaki Y, Asada Y.
(*corresponding author)

Podoplanin expression in advanced atherosclerotic lesions of human aortas

Thromb. Res. 129: 70-76, 2012 (pdf)（宮崎大学との共同研究@山形大学）
38．Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, Steeg PS, Price JE.

The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model.

BMC Cancer.;12(1):583. [Epub ahead of print], on line (pdf)（@MDアンダーソン癌センター）
37．Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, Namba H, Nakazato Y, Tashiro H, Takeuchi I, Mori T, Wakabayash T.

Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas with integrated genomic and epigenetic profiles

Cancer Sci.,103(10):1871-9., 2012 (pdf)（名古屋大学との共同研究@山形大学）
36．Kaji C, Tomooka M, Kato Y, Kojima H, Sawa Y

The expression of podoplanin and classical cadherins in the brain

J Anat. ;220(5):435-46, 2012 (pdf)（福岡歯科大学との共同研究@山形大学） DOI: 10.1111/j.1469-7580.2012.01484.x
35．Kwon MJ, Kim ST, Kwon MJ, Kong DS, Lee D, Park S, Kang SY, Song JY, Nam DH, Kato Y, Choi YL, Suh YL.

IDH1 mutation is a favorable prognostic factor for type 2 gliomatosis cerebri

Brain Pathol. ;22(3):307-317, 2012（韓国との共同研究@山形大学）
34．Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kato Y*(*corresponding author)

Establishment of a novel monoclonal antibody SMab-1 specific for IDH1 R132S mutation.

Biochem Biophys Res Commun., 406(4), 608-613,2011 (pdf)（山形大学法医学との共同研究@山形大学）
33．Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, Yamazaki K, Kato Y, Matsumura A

Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing

Brain Tumor Pathology., 28(2), 115-123, 2011 (pdf)（筑波大学との共同研究@山形大学）
32．Kato Y*, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR.(*corresponding author)

Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas

Nuclear Medicine & Biology.,37(7), 785-794 ,2010 (pdf)（@Duke大学）
31．Chaipan C, Steffen I, Tsegaye TS, Bertram S, Glowacka I, Kato Y, Schmokel J, Munch J, Gerardy-Schahn R, and Pohlmann S.

Incorporation of podoplanin into human immunodeficiency virus particles released from HEK-293T cells, but not PBMC, is required for efficient binding to the attachment factor CLEC-2 and transmission to target cells

Retrovirology, 19;7(1):47, 2010 (PDF)
30．Kato Y*, Kuan CT, Chang J, Kaneko MK, Ayriss J, Piao H, Chandramohan V, Pegram C, McLendon RE, Fredman P, Mansson JE, Bigner DD.(*corresponding author)

GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.

Biochem Biophys Res Commun., 391(1), 750-755, 2010 (PDF)（Duke大学での仕事）
29．Kato Y*, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD(*corresponding author)

A Monoclonal Antibody IMab-1 Specifically Recognizes IDH1R132H, the Most Common Glioma-Derived Mutation.

Biochem Biophys Res Commun., 390(3), 547-551, 2009. (PDF)（Duke大学での仕事）
28．Yamanaka M, Kato Y, Angata T, Narimatsu H.

Deletion polymorphism of SIGLEC14 and its functional implications.

Glycobiology, 19(8):841-6, 2009. (PDF)
27．Kuno A, Kato Y (double first), Matsuda A, Kaneko MK, Ito H, Amano K, Chiba Y, Narimatsu H, Hirabayashi J.

Focused differential glycan analysis with the platform antibody-assisted lectin profiling (ALP) for glycan-related biomarker verification.

Molecular & Cellular Proteomics, 8:99-108, 2009. (PDF)
26．Ogasawara S, Kaneko MK, Price JE, Kato Y*.(*corresponding author)

Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.

Hybridoma, 27(4), 259-267, 2008 (PDF)
25．Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, Arai H, Tsuruo T, Fujita N.

Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis.

Blood, 112(5), 1730-1739, 2008 (PDF)
24．Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, Kato Y*(*corresponding author)

Podocalyxin expression in malignant astrocytic tumors

Biochem Biophys Res Commun. 374(2):394-8, 2008
23．Kato Y*, Hayatsu N, Kaneko MK, Ogasawara S, Hamano T, Takahashi S, Nishikawa R, Matsutani M, Mishima K, Narimatsu H.(*corresponding author)

Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors.

Biochem Biophys Res Commun., 369(4):1041-1046, 2008
22．Amano K, Chiba Y, Kasahara Y, Kato Y, Kaneko MK, Kuno A, Ito H, Kobayashi K, Hirabayashi J, Jigami Y, Narimatsu H.

Engineering of mucin-type human glycoproteins in yeast cells.

Proc Natl Acad Sci U S A., 105, 3232-3237, 2008
21．Hayatsu N, Ogasawara S, Kaneko MK, Kato Y*, Narimatsu H.(*corresponding author)

Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells.

Biochem Biophys Res Commun, 368, 217-222, 2008
20．Kato Y*, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y and Narimatsu H.(*corresponding author)

Molecular analysis of pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.

Cancer Sci, 99(1), 54-61,2008
19．Suzuki H, Kato Y* (double first), Kaneko MK, Okita Y, Narimatsu H, and Kato M.(*corresponding author)

Induction of podoplanin by transforming growth factor-β in human fibrosarcoma.

FEBS lett., 582, 341-345, 2008
18．Hasegawa Y, Kato Y* (double first), Kaneko MK, Ogasawara S, Shimazu M, Tanabe M, Kawachi S, Obara H, Shinoda M, Kitagawa Y, Narimatsu H, Kitajima M.(*corresponding author)

Neutralization of blood group A-antigen by a novel anti-A antibody: overcoming ABO-incompatible solid organ transplantation.

Transplantation. 85(3):378-385, 2008
17．Kaneko MK, Kato Y (double first), Kameyama A, Ito H, Kuno A, Hirabayashi J, Kubota T, Amano K, Chiba Y, Hasegawa Y, Sasagawa I, Mishima K, Narimatsu H.

Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor.

FEBS Lett., 581(2):331-336, 2007
16．Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, Narimatsu H, Ozaki Y.

Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation by cancer cells.

J Biol Chem. 282(36):25993-26001, 2007
15．Kunita A., Kashima T., Morishita Y., Fukayama M., Kato Y., Tsuruo T., Fujita N.

The platelet aggregation-inducing factor Aggrus/podoplanin promotes pulmonary metastasis.

Am J Pathol., 170(4):1337-1347, 2007
14．Kato Y.*, Kaneko MK., Kuno A., Uchiyama N., Amano K., Chiba Y., Hasegawa Y., Hirabayashi J., Narimatsu H., Mishima K., Osawa M.(*corresponding author)

Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet- aggregation-stimulating domain.

Biochem Biophys Res Commun., 349(4):1301-1307, 2006
13．Kaneko MK, Kato Y, Kitano T, Osawa M.

Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor.

Gene, 378C:52-57, 2006
12．Mishima K, Kato Y*, Kaneko MK, Nishikawa R, Hirose T, Matsutani M.(*corresponding author)

Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression.

Acta Neuropathol (Berl).111(5):483-488, 2006
11．Mishima, K., Kato Y*, Kaneko, MK., Nakazawa, Y., Kunita, A., Fujita, N., Tsuruo, T., Nishikawa, R., Hirose, T., Matsutani, M.(*corresponding author)

Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma.

Acta Neuropathol (Berl). 111(6):563-568. 2006
10．Kato Y., Kaneko, M., Sata, M., Fujita, N., Tsuruo, T., Osawa, M.

Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet aggregation-inducing factor in lung squamous cell carcinoma.

Tumor Biol. 26 (4) 195-200, 2005
9．Kato Y., Sasagawa, I., Kaneko, M., Osawa, M., Fujita, N., Tsuruo, T.

Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors.

Oncogene. 23, 8552-8556, 2004
8．Kaneko, M., Kato Y., Kunita, A., Fujita, N., Tsuruo, T., Osawa, M.

Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells.

J Biol. Chem. 279 ,38838-38843, 2004
7．Kato Y., Fujita, N., Kunita, A., Sato, S., Kaneko, M., Osawa, M. and Tsuruo, T.

Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors.

J Biol. Chem. 278, 51599-51605, 2003.
6．Kaneko M, Kato Y, Osawa M.

Molecular characterization of a human monoclonal antibody to B antigen in ABO blood type.

Immunol Lett. 2003 Mar 3;86(1):45-51.
5．Kato Y, Arakawa E, Kinoshita S, Shirai A, Furuya A, Yamano K, Nakamura K, Iida A, Anazawa H, Koh N, Iwano A, Imura A, Fujimori T, Kuro-o M, Hanai N, Takeshige K, Nabeshima Y.

Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys.

Biochem Biophys Res Commun. 2000 Jan 19;267(2):597-602.
4．Kato Y, Hori S, Fujita N, Tsuruo T.

A novel anti-platelet monoclonal antibody induces mouse platelet aggregation through an Fc receptor-independent mechanism.

Biochem Biophys Res Com., 1998 Jan 14;242(2):250-5.
3．Kato Y, Fujita N, Yano H, Tsuruo T.

Suppression of experimental lung colonization of mouse colon adenocarcinoma 26 in vivo by an anti-idiotype monoclonal antibody recognizing a platelet surface molecule.

Cancer Res. 1997 Jul 15;57(14):3040-5.
2．Fujita N, Kodama N, Kato Y, Lee SH, Tsuruo T.

Aggregation of Thy-1 glycoprotein induces thymocyte apoptosis through activation of CPP32-like proteases.

Exp Cell Res. 1997 May 1;232(2):400-6.
1. Fujita N, Kato Y, Naito M, Tsuruo T.

A novel anti-Thy-1 (CD90) monoclonal antibody induces apoptosis in mouse malignant T-lymphoma cells in spite of inducing bcl-2 expression.

Int J Cancer. 1996 May 16;66(4):544-50.
＊PubMed：加藤の2003年以降の業績　
＊Google scholar：加藤の業績の引用